| Mar 3, 2026 | Alveus Therapeutics | $197.0M Series A Extension | Andera Partners, New Rhein Healthcare Investors | Rafaèle Tordjman, Kurma Partners, Novo Holdings, Omega Funds, Sanofi Ventures |
| Jan 8, 2026 | Alveus Therapeutics | $160.0M Series A | Jan Van den Bossche, Nayan Parekh, Claudio Nessi | Kurma Partners, Sanofi Ventures |
| Jan 8, 2026 | EpiBiologics | $107.0M Series B | Anika Gupta, Johnson & Johnson Innovation | Nisa Leung, Eric Pham, Codon Capital, Laura Brass, Mitchell Mutz, Gaurav Aggarwal, Digitalis Ventures, Mission BioCapital, Polaris Partners, Taiho Ventures |
| Nov 11, 2025 | myTomorrows | $29.0M Other Equity | James Flexner | — |
| Jul 1, 2025 | MapLight Therapeutics | $370.0M Series D | Forbion | EQT Life Sciences, Soffinova Partners, 5AM Ventures, Novo Holdings, Sanofi, T. Rowe Price Associates |
| May 1, 2025 | CellCentric | $120.0M Series C | Forbion, RA Capital Management | ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, HealthCap, INKEF Capital, Pfizer Venture Investments, Pontifax Venture Capital, RA Capital, SR One, Bill Gates, American Cancer Society, BrightEdge |
| Nov 1, 2024 | TRex Bio | $84.0M Series B | Eric Huang | Polaris Partners, Agent Capital, Joel Marcus, Eric Pham, Eli Lilly and Company, Johnson & Johnson Innovation, Polaris Partners, SV Health Investors |
| Nov 1, 2022 | Escient Pharmaceuticals | $120.0M Series C | Abingworth, Forge Life Science Partners, NEA | 5AM Ventures, Access Biotechnology, Atlas Venture, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, Sanofi Ventures, The Column Group, Altitude Life Science Ventures, Cowen Healthcare Investments, PFM Health Sciences, Redmile Group, The Eleven Fund |
| Aug 24, 2022 | AtomVie Global Radiopharma | $40.0M Series A | Thomas Vandervort | — |
| Nov 1, 2021 | Antios Therapeutics | $75.0M Series B | EPIQ Capital Group, Craig Gordon | Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, CAM Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, Heartland Healthcare Capital, LifeSci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital, Soleus Capital |
| Jul 14, 2021 | Ribon Therapeutics | $65.0M Other Equity | Cameron Wheeler, U.S. Venture Partners | AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Google Ventures, Johnson & Johnson Innovation, Monashee Investment Management, Novartis, Osage University Partners, Peregrine Ventures, Takeda Ventures, The Column Group |
| Mar 1, 2021 | Caribou Biosciences | $120.0M Series C | Farallon Capital Management, Santhosh Palani, PhD, CFA, Jeffrey Long-McGie | 1435 Capital Management, 6th Man Ventures, Afore Capital, DFJ, E1 Ventures, Flucas Ventures, Founders Co-op, Heavybit, Invariantes Fund, Kleiner Perkins, KRM Interests LLC, LombardStreet Ventures, Maverick Capital, Menlo Ventures, Mouro Capital, Necessary Ventures, QED Investors, Robert Bosch Venture Capital, Starbridge Venture Capital, Sterling Equity, William Guo, XStarPartners, Adam Marchick, Andy Rubin, Dylan Taylor, hugo angelmar, Ravi Grover, Richard Cooperstein, Rob Meyerson, Sri Batchu, Sung ho Choi, AbbVie Ventures, Adage Capital Management, Avidity Partners, Heritage Medical Systems, Invus, Janus Henderson Investors, LifeSci Venture Partners, Maverick Ventures, Monashee Investment Management, Point72, Pontifax, Tekla Capital Management, The Leukemia & Lymphoma Society |
